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Background
Nonalcoholic steatohepatitis (NASH) is characterized by
accumulation of fat in the liver without excessive alcohol
intake [1]. The optimal treatment for this disease is
not well established, however, metformin is described as
an efficient treatment for NASH and hepatic inflamma-
tion [2]. Based on these data, the present study aimed
to evaluate the possible immune-metabolic effects of
metformin in high-fat diet wild type (C57) and knockout
for PPAR-alpha (KO) mice.
Materials and methods
C57 and KO mice were submitted to a balanced or high
fat diet (HFD) for 12 weeks, after 10 weeks these animals
were treated with metformin or phosphate buffered saline
by gavage. The insulin tolerance test (ITT) and glucose
tolerance test (GTT) were performed. Histological slices of
the liver, cored by hematoxilin and eosin were obtained,
and the concentration of triacylglycerols and the cytokines
levels were determined by ELISA.
Results
Animals submitted to HFD showed higher gain of weight
(C57 p<0.001;KO p<0.05), that in C57 was represented by
a greater gain of adipose tissue (p<0.001), while the weight
of the liver did not change. This diet promotes insulin
resistance in C57 and KO, as observed by reduction of
glycemia in ITT (p<0.05) and by an increase in GTT
(p<0.001). Although no differences in liver weight were
observed in KO, these animals showed higher hepatic
deposition of triacylglycerols (p<0.01) and more severe
steatosis without an increase of pro-inflammatory
cytokines levels. After 7 days, both C57 and KO treated
with metformin showed an improvement in glucose
tolerance in the GTT (p<0.05), and after 10 days metfor-
min reduced the steatosis as evidenced by histology.
Controversially, the liver of C57 mice submitted to HFD
and treated with metformin showed higher levels of IL1-b
(p<0.05), IL-8 and IL-12 (p<0.01).
Conclusion
The treatment with metformin improves glucose tolerance
and decreases steatosis in mice submitted to high fat diet.
However, the treatment was not able to reverse the
inflammation in C57 mice. The mechanism of metformin
is independent of PPAR-alpha.
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